Recent Finacing
Recent Raise
Phathom Pharmaceuticals develops and commercializes gastrointestinal therapies, holding an exclusive Takeda license to develop and commercialize the P-CAB vonoprazan in the United States, Europe, and Canada.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Phathom Pharmaceuticals.
